Journal of Cystic Fibrosis, Volume 14, Supplement 1, June 2015, Pages S52
Abstracts of the 38th European Cystic Fibrosis Conference. Oral Presentation ePS05.9
L. Hanssensa, I. Thiébaulta, N. Lefevrea, A. Malfrootb, V. Gaspara, C. Knoopc, J. Duchateaud, G. Casimira
Clinical symptoms and lung function of CF may be influenced by correcting essential fatty acids (EFA) deficiency. Nevertheless, the value of EFA supplementation in CF remains controversial.
Objectives: The aim of this longitudinal randomized double-blind placebo-controlled clinical trial was to assess the benefits of an oral supplementation with omega-3 on clinical and nutritional status, lung function and exercise tolerance.
Methods: A supplementation with a triglyceride source of omega-3 (Omega 3 Premium®, Laboratoires Ponroy, France) at a daily dose of 60 mg/kg during 1 year was administered to ΔF508 homozygous CF patients above 5 years of age. Patients were assessed at 3, 6, 9 and 12 months. Lung function was performed at each visit and an exercise test before and at the end of study.
Results: Of the 16 patients included, 13 completed the study. Six received omega-3 and 7 the placebo. Compared to the control group the cumulative duration of antibiotic therapy decreased in the intervention group at 9 months (24.5 days vs 46.0 days, p = 0.02) and at 12 months (26.5 days vs 65.0 days, p<0.02). Compared to the previous year the number of exacerbations at 12 months decreased (1.7 vs 3.5, p<0.01) and also the cumulative duration of antibiotic therapy (26.5 days vs 60.5 days, p<0.02). No difference was observed in lung function and exercise test. Supplementation was well tolerated.
Conclusions: This longitudinal randomized placebo-controlled study shows some clinical benefits of long-term omega-3 supplementation in CF patients. However, additional studies with larger populations are needed.